Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, largely driven by KRAS mutations.
• Direct KRAS inhibition is limited by mutation rarity, modest efficacy, and resistance.
• Existing indirect KRAS targeting approaches have shown limited success or toxicity.

Purpose of the Study:

• To evaluate therapeutic synergisms of KRAS inhibitors, MEK inhibitors, and irradiation in PDAC cell lines.
• To investigate mechanisms of resistance and potential combination therapies for KRAS-mutated PDAC.
• To identify effective strategies for overcoming limitations in current KRAS-targeted therapies.

Main Methods:

• Treatment of PDAC cell lines (KRAS G12C, G12D, wild-type) with KRAS or SOS1/2 inhibitors.
• Assessment of therapeutic synergism using cell viability, clonogenic, soft agar, and ATP assays.
• Examination of underlying mechanisms via Western blot, apoptosis, and RAS activation assays.

Main Results:

• Systematic evaluation of combined therapeutic modalities including MEK inhibition and irradiation.
• Investigation into synergistic effects and resistance mechanisms in various PDAC models.
• Analysis of molecular underpinnings of treatment response and resistance.

Conclusions:

• Novel combination strategies are needed to effectively target KRAS in PDAC.
• Synergistic effects of combined therapies may overcome resistance and improve outcomes.
• Further research into combined KRAS inhibition, MEK inhibition, and irradiation is warranted for PDAC treatment.